OMX30 1 580 -0,1%  OMXH25 3 773 -0,4%  OMXC20 904 0,0%  Dow 20 597 -0,3%  Nas 5 364 0,2%  EUR 9,5165 0,0%  USD 8,8095 0,0%  Olja 51,0 0,9%  Guld 1 255 0,8% 

Hologic Aktie

42,30USD 0,08USD 0,19%
<
Bolag
Terminer
Profil
>
<
Relaterade värdepapper
ETP:er
Obligationer
>

Fundamentala nyckeltal för Hologic

2016 2017e 2018e 2019e 2020e
Utdelning - - - - -
Direktavkastning (i %) - - - - -
PE-tal 19,44 21,73 19,82 17,90 15,81
Resultat/aktie 1,96 1,94 2,12 2,35 2,66

Nyheter om Hologic IncShs

Inga nyheter tillgängliga
ytterligare nyheter

Analyser om Hologic IncShs

ytterligare analyser

Hologic Peer Group

Becton, Dickinson & 183,89
0,1%
Boston Scientific 24,33
0,3%
CR Bard 249,88
0,5%
Carl Zeiss Meditec 38,94
0,0%
Hologic 42,30
0,2%
pagehit

Lägg till instrument

Vad tycker du?

Profil Hologic IncShs

till bolagsprofilen
Hologic, Inc. engages in the development, manufacture and supply diagnostics products, medical imaging systems and surgical products dedicated to serve the healthcare needs of women. The company operates through four business segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. The Breast Health segment products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, magnetic resonance imaging, breast coils, computer-aided detection for mammography and MRI, minimally invasive breast biopsy devices, breast biopsy site markers, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products. It has also developed a new breast imaging platform, Dimensions, which utilizes a new technology, tomosynthesis, to produce three dimensional images, as well as conventional two dimensional full field digital mammography images. The Diagnostics segment products include the ThinPrep system, which is primarily used in cytology applications such as cervical cancer screening, the Rapid Fetal Fibronectin Test, which assists physicians in assessing the risk of pre-term birth, and its molecular diagnostic reagents used for a variety of DNA and RNA analysis applications based on its proprietary Invader chemistry. Its current molecular diagnostic offerings based upon this Invader chemistry include Cervista HPV high risk and Cervista HPV 16/18 products to assist in the diagnosis of human papillomavirus, as well as other products to diagnose cystic fibrosis, cardiovascular risk and other diseases. The GYN Surgical segment products include the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The MyoSure system is a tissue removal device that is designed to provide incision-less removal of fibroids and polyps within the uterus. The Skeletal Health segment products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in October, 1985 and is headquartered in Bedford, MA.

Realtidskurs Hologic IncShs

Bid
42,29
USD
Ask
42,32
USD
Kurstid
21:00
Börsen BTT

Aktiekurs Hologic IncShs i USDPUSH CHART

Kurs 42,30 USD 0,08 0,19 %
Kurstid 21:00:02
Datum 24.03.2017
Öppning 42,27
Gårdagen 42,30
Dagshögsta 42,55
Dagslägsta 42,12
52 v. högsta 42,96
52 v. lägsta 32,64
52 v. perf.
Volym (Antal) 111 189
Börsvärde (SEK) 103,16 Mrd
Börsen
Kurs för 42,30 USD från börsen BATS Trading motsvarar med aktuell växelkurssentspricht USD/SEK en kurs på 372,64 SEK.

Till aktien Hologic

Ticker
ISIN US4364401012
Index S&P 500, NASDAQ 100

Hologic Nyckeltal

Börsvärde i SEK 103,16 Mrd
Free float % 99,48
Antal aktier mio. 279,30
Cashflow/aktie i lokal valuta 2,52
Bokvärde/aktie i lokal valuta 7,65
60 dagar vola 20,65
PBV 4,98

Hologic Historiska kurser

2017-03-24 42,30 111 189
2017-03-23 42,22 100 084
2017-03-22 42,10 139 724
2017-03-21 41,95 158 570
2017-03-20 42,41 96 864

Aktier i samma industri med bättre 1 års perf.

Merge Healthcare Inc Cash Settlement At USD 7.13 A Sh 219,3 %
Thoratec Corp. 143,0 %
Urologix Inc. 113,0 %
Hanger Inc. 97,7 %
Cutera Inc. 92,0 %